194 related articles for article (PubMed ID: 9852086)
1. Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
Pelemans H; Esnouf RM; Jonckheere H; De Clercq E; Balzarini J
J Biol Chem; 1998 Dec; 273(51):34234-9. PubMed ID: 9852086
[TBL] [Abstract][Full Text] [Related]
2. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
[TBL] [Abstract][Full Text] [Related]
3. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
Menéndez-Arias L; Betancor G; Matamoros T
Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
6. Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors.
Auwerx J; North TW; Preston BD; Klarmann GJ; De Clercq E; Balzarini J
Mol Pharmacol; 2002 Feb; 61(2):400-6. PubMed ID: 11809865
[TBL] [Abstract][Full Text] [Related]
7. Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability.
Figueiredo A; Zelina S; Sluis-Cremer N; Tachedjian G
Curr HIV Res; 2008 Mar; 6(2):130-7. PubMed ID: 18336260
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
Das K; Sarafianos SG; Clark AD; Boyer PL; Hughes SH; Arnold E
J Mol Biol; 2007 Jan; 365(1):77-89. PubMed ID: 17056061
[TBL] [Abstract][Full Text] [Related]
9. A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
Harrigan PR; Salim M; Stammers DK; Wynhoven B; Brumme ZL; McKenna P; Larder B; Kemp SD
J Virol; 2002 Jul; 76(13):6836-40. PubMed ID: 12050397
[TBL] [Abstract][Full Text] [Related]
10. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
[TBL] [Abstract][Full Text] [Related]
11. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
12. Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.
Peletskaya EN; Kogon AA; Tuske S; Arnold E; Hughes SH
J Virol; 2004 Apr; 78(7):3387-97. PubMed ID: 15016861
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors.
Pelemans H; Esnouf R; De Clercq E; Balzarini J
Mol Pharmacol; 2000 May; 57(5):954-60. PubMed ID: 10779379
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus mutagenesis during antiviral therapy: impact of drug-resistant reverse transcriptase and nucleoside and nonnucleoside reverse transcriptase inhibitors on human immunodeficiency virus type 1 mutation frequencies.
Chen R; Yokoyama M; Sato H; Reilly C; Mansky LM
J Virol; 2005 Sep; 79(18):12045-57. PubMed ID: 16140780
[TBL] [Abstract][Full Text] [Related]
16. A proline-to-histidine substitution at position 225 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitizes HIV-1 RT to BHAP U-90152.
Pelemans H; Esnouf RM; Parniak MA; Vandamme AM; De Clercq E; Balzarini J
J Gen Virol; 1998 Jun; 79 ( Pt 6)():1347-52. PubMed ID: 9634074
[TBL] [Abstract][Full Text] [Related]
17. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
18. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
[TBL] [Abstract][Full Text] [Related]
20. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
Sluis-Cremer N; Temiz NA; Bahar I
Curr HIV Res; 2004 Oct; 2(4):323-32. PubMed ID: 15544453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
